Zoetis Inc. $ZTS Holdings Cut by New Hampshire Trust

New Hampshire Trust lowered its stake in Zoetis Inc. (NYSE:ZTS) by 5.7% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,767 shares of the company’s stock after selling 589 shares during the period. New Hampshire Trust’s holdings in Zoetis were worth $1,523,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in ZTS. Nova Wealth Management Inc. bought a new stake in shares of Zoetis during the first quarter valued at approximately $25,000. 1248 Management LLC bought a new stake in Zoetis during the 1st quarter worth approximately $27,000. Saudi Central Bank acquired a new position in Zoetis during the 1st quarter worth about $29,000. REAP Financial Group LLC increased its position in Zoetis by 201.5% in the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock worth $31,000 after purchasing an additional 131 shares during the period. Finally, Cornerstone Planning Group LLC boosted its stake in Zoetis by 79.3% in the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock valued at $30,000 after acquiring an additional 88 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on ZTS shares. UBS Group reduced their price objective on Zoetis from $165.00 to $158.00 and set a “neutral” rating for the company in a research report on Monday, October 20th. Leerink Partners lowered shares of Zoetis from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Weiss Ratings restated a “hold (c-)” rating on shares of Zoetis in a research note on Friday. Argus restated a “buy” rating and issued a $190.00 price target on shares of Zoetis in a research note on Tuesday, September 9th. Finally, Leerink Partnrs cut shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Four equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $195.00.

Zoetis Price Performance

ZTS stock opened at $146.14 on Friday. The company has a fifty day moving average price of $148.18 and a 200-day moving average price of $153.57. The company has a market capitalization of $64.77 billion, a P/E ratio of 25.15, a PEG ratio of 2.35 and a beta of 0.90. Zoetis Inc. has a 52-week low of $139.34 and a 52-week high of $184.40. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company had revenue of $2.46 billion during the quarter, compared to analysts’ expectations of $2.41 billion. During the same quarter in the prior year, the firm posted $1.56 earnings per share. The business’s quarterly revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.4%. The ex-dividend date of this dividend is Friday, October 31st. Zoetis’s payout ratio is currently 34.42%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.